The FDA has given orphan drug status to Osiris Therapeutics' Prochymal adult stem cell product, which is being investigated as a treatment for acute Graft vs. Host Disease. Prochymal is intended to modulate the body's immune system. The FDA put Prochymal on a fast track back in January. Release [1]